News briefing: Kite looks to expand Yescarta franchise with new indications; Tiny Lixte looks to uplist on Nasdaq
A little more than a month after gaining their first OK for their second CAR-T, Gilead’s Kite is in hot pursuit of an expanded use for their pioneering Yescarta.
The Gilead subsidiary has filed for an approval to market the CAR-T as a third-line therapy for relapsed or refractory follicular lymphoma and marginal zone lymphoma. Given the FDA’s breakthrough therapy designation here, as well as Yescarta’s track record, and you have an odds-on success.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.